Tempus AI Growth Strong but Economics Lag; WAIT Rating Affirmed

What happened

Tempus AI reported robust Q1 2026 data segment revenue growth of 40% YoY to $87M, with MRD testing volume surging 500% YoY, driven by a partnership with Personalis. However, ~97% of MRD volume remains low-fee distributor-style testing with an ASP around $470, limiting margin contribution. The DeepValue report maintains a WAIT rating, citing no margin of safety at the current ~$60 price and the need for observable improvements in oncology ASP, cash burn, and data contract renewal quality. While the news article touts a path to $500M+ data revenue and a Strong Buy, the filings reveal that data contracts often have opt-out rights after 12 months, and a key data license ended in Q1 2026. Until Q2-Q3 evidence shows ASP above $1,800, cash burn below $40M quarterly, and sustained data growth, the investment thesis remains unproven.

Implication

In the near term, investors should not buy Tempus AI based solely on volume growth or bullish analyst ratings. The stock lacks a margin of safety and prices in improvements that have not yet materialized. The critical catalysts are: oncology ASP rising from ~$1,720, quarterly cash burn declining from $83.6M, and evidence that data contracts convert into recognized revenue after initial opt-out windows. If Q2 results show any of these inflection points, the thesis improves; otherwise, the bear case of low-margin growth and persistent capital needs becomes more likely. Five-year holders should monitor these milestones and consider entry only at an attractive price near $50 or after tangible financial improvement.

Thesis delta

The narrative is shifting from pure growth to a proof-of-economics stage. While Tempus is winning adoption—data revenue up 40%, MRD volume up 500%—the quality of that growth is weak due to low-margin MRD volume, lumpy data revenue, and high cash burn. The market now needs to see ASP uplift, cash burn reduction, and renewal quality, not just top-line expansion.